Home / Guides / Medications
Medications

Zepbound for Sleep Apnea: The First FDA-Approved Drug for OSA

In December 2024, Zepbound became the first medication ever FDA-approved for obstructive sleep apnea — a condition affecting 30 million U.S. adults and previously treated only with CPAP, oral appliances, or surgery.

Published March 15, 2026 · 8 min read
Last reviewed: March 15, 2026 by our editorial team. See our editorial process.

Bottom line

In December 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — the first time any drug has received an OSA indication. It is not a CPAP replacement for most patients, but it is a genuine alternative or adjunct that has changed the treatment landscape.

In the SURMOUNT-OSA trials, patients on tirzepatide 10-15 mg had a mean reduction of 25-30 apnea-hypopnea events per hour over 52 weeks, compared to 5 on placebo. About 40-50% of treated patients achieved clinically meaningful resolution (AHI below 5 or reduction of 50% or more).

What OSA is and why weight matters so much

Obstructive sleep apnea is characterized by repeated partial or complete airway collapse during sleep, measured by the apnea-hypopnea index (AHI — events per hour). Severity:

OSA affects an estimated 30 million U.S. adults and is severely underdiagnosed — roughly 80% of moderate-to-severe cases remain undiagnosed. Consequences include cardiovascular disease, hypertension, atrial fibrillation, stroke, daytime sleepiness, motor vehicle accidents, and increased mortality.

Obesity is the single strongest modifiable risk factor. Fat deposition around the upper airway (tongue base, soft palate, pharyngeal walls) narrows the airway mechanically. Fat around the chest and abdomen reduces lung volumes and changes upper airway dynamics during sleep. The relationship is roughly linear: every 10% increase in body weight is associated with a six-fold increase in OSA risk.

The mechanism works in reverse, too. Weight loss of 10-15% typically reduces AHI by 50% or more in moderate cases. Historically, achieving that level of weight loss with diet and exercise alone was rare — which is why CPAP became the default treatment despite its well-known adherence problems.

The SURMOUNT-OSA evidence in detail

Two parallel randomized, double-blind, placebo-controlled trials enrolled 469 adults with moderate-to-severe OSA (AHI 15 or higher) and obesity (BMI 30 or higher). Mean baseline AHI was approximately 51 events per hour in OSA-1 and 49 in OSA-2 — solidly in the severe range. Mean baseline BMI was approximately 39 in both trials.

SURMOUNT-OSA-1 enrolled patients not using CPAP at baseline (either newly diagnosed, CPAP-intolerant, or CPAP-refusing). Tirzepatide reduced AHI by a mean of 25.3 events/hour versus 5.3 on placebo — a difference of 20 events/hour. About 42% achieved AHI below 5 (clinical resolution) or a 50% or greater reduction in AHI, compared to 14% on placebo.

SURMOUNT-OSA-2 enrolled patients already using CPAP at baseline. Tirzepatide reduced AHI by a mean of 29.3 events/hour versus 5.5 on placebo. About 50% achieved AHI below 5 or a 50% or greater reduction, compared to 14% on placebo. The fact that tirzepatide added benefit on top of CPAP is significant — it suggests the mechanisms are complementary.

Both trials saw mean body weight reductions of 17-19% on tirzepatide. Patients also reported improvements in daytime sleepiness (Epworth Sleepiness Scale), sleep quality, and quality of life measures.

Importantly, the AHI benefit was larger in both trials than would be predicted by weight loss alone — suggesting tirzepatide may have additional effects on airway inflammation, fluid distribution, or upper airway muscle function beyond what weight loss explains.

How much weight loss actually impacts AHI

Not all weight loss is equal for OSA. Research consistently shows that the relationship between weight loss and AHI improvement is non-linear:

change severity category. Patients may feel somewhat better but usually still need CPAP.

cases drop to mild or resolve entirely. This is the threshold where CPAP reduction becomes a real conversation.

level, even many severe cases see clinically meaningful improvement, and a substantial minority achieve resolution.

The SURMOUNT-OSA data, with its 17-19% average weight loss, sits squarely in the most impactful range.

Timeline for sleep improvements

Patients often want to know how quickly they will sleep better. The honest answer: it varies, but the pattern is roughly predictable.

during dose titration. Some patients report modest improvements in daytime energy, possibly from GLP-1 effects on sleep architecture independent of weight loss.

accelerates. Patients on CPAP may notice their pressures feel too high (a sign the airway is opening).

studies become informative and CPAP reduction or discontinuation decisions can be made.

Your prescriber and sleep physician should coordinate on timing for repeat testing. Getting a new sleep study too early wastes money and may not reflect the full benefit.

Zepbound vs CPAP vs surgery

Each approach has a different profile:

CPAP remains the gold standard for immediate, reliable AHI reduction. It works the first night. Adherence is the problem — estimates suggest only 50-70% of patients use CPAP consistently, and many abandon it entirely. CPAP does not address the underlying cause (weight-related airway narrowing); it manages the symptom.

Surgery (uvulopalatopharyngoplasty, maxillomandibular advancement, hypoglossal nerve stimulation) is effective for selected patients but invasive, expensive, and irreversible. Success rates vary widely by procedure and patient anatomy.

Zepbound addresses the root cause in patients whose OSA is obesity-driven. It is slower than CPAP (months vs. one night) but treats the underlying problem. For patients who cannot tolerate CPAP, it is the first proven pharmacological alternative. For patients on CPAP, it may eventually allow them to reduce or stop CPAP use.

The emerging best practice is combination: CPAP for immediate symptom management while Zepbound addresses the underlying weight. Consult a prescriber and your sleep physician to determine the right approach for your situation.

Is Zepbound going to replace your CPAP?

For most patients, no — at least not immediately. CPAP remains the first-line treatment for moderate-to-severe OSA with higher and faster efficacy. But Zepbound creates real options:

diagnosed OSA patients) now have a proven alternative.

achieving sufficient weight loss (typically 15%+).

on Zepbound alone.

A typical prescriber playbook in 2026: start Zepbound, maintain CPAP through weight loss, repeat sleep study at 6-12 months, consider CPAP reduction or discontinuation if AHI has normalized.

What happens if you stop Zepbound

This is the question patients need to ask. The SURMOUNT-4 withdrawal data (from the obesity indication, not OSA specifically) showed that patients who stopped tirzepatide regained approximately two-thirds of lost weight within 12 months. For OSA patients, that weight regain would be expected to bring AHI back up.

In practical terms: if you achieve OSA resolution on Zepbound and then stop the medication, your sleep apnea will very likely return as weight returns. Most sleep medicine specialists currently recommend planning for long-term use if Zepbound is your primary OSA treatment.

Who benefits most

The best candidates for Zepbound for OSA are patients who have:

anatomy-driven)

Patients with primarily anatomical OSA (narrow jaw, large tonsils, deviated septum) may see less benefit from weight loss alone. Consult a prescriber who can evaluate both your sleep study results and your overall medical profile.

Why not Wegovy or Ozempic?

Only Zepbound has the FDA approval for OSA. Semaglutide (Wegovy, Ozempic) likely produces similar benefits proportional to its weight loss effect, but Novo Nordisk has not run the analogous trial yet.

For off-label use, Wegovy is a reasonable alternative for patients whose insurance covers it but not Zepbound.

Coverage: the biggest change in years

The Zepbound OSA approval has materially expanded insurance coverage. OSA is a covered medical diagnosis on essentially every commercial plan and Medicare — unlike "obesity," which Medicare Part D cannot cover.

Medicare Part D has begun covering Zepbound for OSA in patients with documented moderate-to-severe OSA and qualifying BMI as of 2025. This is the first time Medicare has covered a GLP-1 for weight-related indications beyond the Wegovy/CVD carve-out.

Commercial plans have rapidly expanded OSA coverage for Zepbound through 2025 — often requiring a documented sleep study (home sleep apnea test or in-lab polysomnography) and AHI of 15 or higher.

If you have OSA and have struggled to get GLP-1 coverage through the obesity pathway, the OSA pathway may succeed. Ask your prescriber whether your sleep study supports the diagnosis. Having a formal sleep study on file — not just a self-report of snoring — is essential for insurance approval.

What to discuss with your sleep physician

sense.

patients develop aerophagia on pressures set for a heavier body).

stroke).

treatment — including what happens if you need to stop.

Next steps

If you have OSA and obesity, the Zepbound drug page covers the full efficacy, cost, and dosing picture. The Sherpa Matcher will help you find telehealth programs that handle OSA-indication prescribing.